



Published in final edited form as:

*CNS Drugs*. 2018 December ; 32(12): 1091–1101. doi:10.1007/s40263-018-0582-9.

## Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies

Juliane Gust<sup>1,2</sup>, Agne Taraseviciute<sup>3</sup>, Cameron J. Turtle<sup>4,5</sup>

<sup>1</sup>Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA, USA

<sup>2</sup>Division of Pediatric Neurology, Department of Neurology, University of Washington, Seattle, WA, USA

<sup>3</sup>Department of Pediatrics, University of Southern California, Los Angeles, CA, USA

<sup>4</sup>Clinical Research Division and Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

<sup>5</sup>Department of Medicine, University of Washington, Seattle, WA, USA

### Abstract

Neurotoxicity is an important and common complication of chimeric antigen receptor-T cell therapies. Acute neurologic signs and/or symptoms occur in a significant proportion of patients treated with CD19-directed chimeric antigen receptor-T cells for B-cell malignancies. Clinical manifestations include headache, confusion, delirium, language disturbance, seizures and rarely, acute cerebral edema. Neurotoxicity is associated with cytokine release syndrome, which occurs in the setting of in-vivo chimeric antigen receptor-T cell activation and proliferation. The mechanisms that lead to neurotoxicity remain unknown, but data from patients and animal models suggest there is compromise of the blood–brain barrier, associated with high levels of cytokines in the blood and cerebrospinal fluid, as well as endothelial activation. Corticosteroids, interleukin-6-targeted therapies, and supportive care are frequently used to manage patients with neurotoxicity, but high-quality evidence of their efficacy is lacking.

### 1 Introduction

Chimeric antigen receptor (CAR)-modified T (CAR-T) cell immunotherapy has produced impressive results in clinical trials treating relapsed and/or refractory B-cell malignancies. T cells obtained from the patient, or less often from an allogeneic donor, are modified to express a CAR, which consists of an extracellular tumor-targeting moiety (usually a single-chain variable fragment derived from a tumor-reactive monoclonal antibody) fused to one or more intracellular T-cell signaling domains. On encounter with the antigen to which the

---

Cameron J. Turtle [cturtle@fhcrc.org](mailto:cturtle@fhcrc.org).

Compliance with Ethical Standards

**Conflict of interest** Cameron J. Turtle receives research funding from Juno Therapeutics/Celgene and Nektar Therapeutics; has served on advisory boards for Juno Therapeutics/Celgene, Nektar Therapeutics, Precision Biosciences, Caribou Biosciences, Eureka Therapeutics, Gilead, and Aptevo; and has options in Precision Biosciences, Eureka Therapeutics and Caribou Biosciences. Juliane Gust and Agne Taraseviciute have no conflicts of interest that are directly relevant to the contents of this article.

single-chain variable fragment is directed, the CAR-T cell is activated, resulting in proliferation, cytokine secretion, and target cell lysis [1]. Lymphodepleting chemotherapy is usually administered to patients before CAR-T cell infusion to improve CAR-T cell in-vivo proliferation and potentially limit host T-cell-mediated CAR-T cell rejection. Minimal residual disease-negative complete response rates of 60–93% have been reported in relapsed and refractory acute lymphoblastic leukemia (ALL) [2–8]. Overall response rates of 63–82% in non-Hodgkin's lymphoma (NHL) [9–13] and 39–100% in chronic lymphocytic leukemia (CLL) [10, 14–16] have been noted (Table 1). These data have led to the US Food and Drug Administration (FDA) approval of tisagenlecleucel (Kymriah®; Novartis Pharmaceuticals Corporation, New Jersey, USA) for the treatment of relapsed/refractory B-cell precursor ALL in patients up to 25 years of age [6] and diffuse large B-cell lymphoma in adults [17]. Axicabtagene ciloleucel (Yescarta™; Kite Pharma, Santa Monica, CA, USA) is now approved for relapsed/refractory diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and diffuse large B-cell lymphoma arising from follicular lymphoma in adults [12]. New data are emerging in clinical trials of CAR-T cells targeting numerous other antigens [13, 18, 19].

Chimeric antigen receptor-T cell immunotherapy has the potential for significant, but generally reversible, adverse effects in a subset of patients. Chimeric antigen receptor-T cell proliferation after infusion can lead to hypercytokinemia and systemic cytokine release syndrome (CRS) [20–22]. Neurologic complications are common [23]. The broader application of CAR-T cell therapies in oncology will require a better understanding of the pathophysiology, prevention, and treatment of neurotoxicity.

## 2 Incidence of Neurotoxicity in Published Clinical Trials

The majority of CAR-T cell therapies target CD19 in patients with B-cell malignancies, and neurotoxicity has been reported in all studies that demonstrate robust anti-tumor efficacy (Table 1). The severity of neurotoxicity is graded using different systems in different trials; for the purpose of this overview, neurotoxicity is usually considered severe when it is grade 3 or greater by the Common Terminology Criteria for Adverse Events (v4). The reader should refer to Table 1 and published papers for the definitions of severe neurotoxicity in individual trials.

In studies using CAR constructs with a 4–1BB domain, neurologic adverse events were reported in 40–44% of children and young adults with ALL (13–21% severe) [4, 6], and 50% of adults with ALL (50% severe) [3]. In adults with NHL, neurotoxicity occurred in 28–39% (11–28% severe) [9, 11], and in adults with CLL the incidence was 6–33% (0–25% severe) [14, 16]. In a pediatric ALL trial using a CD19 CAR with a CD28 co-stimulatory domain, neurotoxicity was reported in 30% of children and young adults (5% severe) [5]. In an adult ALL trial using a CD28 co-stimulated CAR 44% of patients (42% severe) developed neurotoxicity [2]. Another adult trial, which used the same CAR construct but a different manufacturing approach, was closed because of a high incidence of fatal neurotoxicity [24]. Forty-five percent of adults with NHL treated with a CD28-containing CD19 CAR developed severe neurotoxicity [10, 25]. The reported prevalence and presentations of neurotoxicity vary widely between these studies and may be affected by

differences in disease, prior treatment history, patient age, CAR design, CAR-T cell manufacturing approach, lymphodepletion regimen, CAR-T cell dose and infusion regimen, product potency and efficacy, toxicity grading schemas, and treatment strategies in each study [22, 26].

Neurotoxicity has also been reported in clinical trials of CAR-T cells directed against targets other than CD19 [27–31]. Among patients treated with CD22-directed CAR-T cells for ALL, 25% developed neurotoxicity, but none had severe neurotoxicity or severe CRS [28]. Eighty-one percent of the patients in the study had previously received CD19 CAR-T cells, and the morphologic complete response rate was 57%. In a trial of CAR-T cells directed against B-cell maturation antigens expressed on multiple myeloma, 25% of patients experienced neurotoxicity (8% severe) [30]. Over-all, the rates of neurotoxicity, CRS, and clinical responses appear lower for non-CD19 CAR-T cells targeting hematologic malignancies (Table 2). Toxicity profiles may change with further development and optimization of these immunotherapies.

While CAR-T cell immunotherapies targeting solid tumors have not yet produced consistent clinical responses, a large number of trials are currently underway or in development [19, 32, 33]. Neurologic symptoms have not been reported in solid tumor CAR-T therapies [34–39] with the exception of brain tumor trials, where it is often difficult to distinguish between disease progression and treatment side effects. Transient focal neurologic symptoms or seizures were observed in 30% of patients treated for glioblastoma with intravenously infused CAR-T cells directed against epidermal growth factor receptor variant III [40], and in 25% of patients treated with intra-cranially delivered CAR-T cells targeting interleukin (IL)-13 receptor subunit alpha 2, with an additional 50% of patients in the IL-13 receptor subunit alpha 2 CAR trial developing severe headache [41, 42].

### **3 Clinical Presentation of Neurotoxicity Associated with CD19 Chimeric Antigen Receptor T Cells**

#### **3.1 Signs and Symptoms**

Chimeric antigen receptor-T cell-associated neurotoxicity comprises a wide range of signs and symptoms, including delirium, headache, language disturbance, tremor, transient focal weakness, behavioral disturbances, ataxia, peripheral neuropathy, visual changes and generalized weakness, seizures, and acute cerebral edema [17, 23, 43, 44]. We recently reported a study of neurotoxicity in 133 adults with ALL, NHL or CLL who received T cells expressing a CD19-targeting CAR with a 4–1BB co-stimulatory domain. In this study, neurotoxicity onset occurred a median of 4 days after CAR-T cell infusion, with a peak on day 7, and a duration of 5 days [23]. The kinetics of presentation may differ between studies investigating different CAR-T cell therapies, and in studies in which dedicated assessment tools are employed to identify early signs of subtle neurotoxicity [6, 11, 23, 28, 44]. Most signs and symptoms of neurotoxicity resolve within 21 days of treatment—persistent abnormalities are uncommon [6, 23].

In our study, the most common sign, present in 66% of patients with neurotoxicity, was transient impairment of attention and cognitive processing, manifesting as delirium or confusion, which were also observed in other trials [6, 11, 23, 28, 44]. Language disturbance, such as word finding difficulty, is frequent and often associated with delirium, as are decreased arousability and somnolence. Headache is very common, and the temporal association with other neurologic signs suggests it is likely a manifestation of neurotoxicity. Seizures are reported with varying incidence. In our 133 adult patients treated with 4–1BB costimulated CAR-T cells seizures were infrequent and only occurred in patients with a prior history of seizures or life-threatening neurotoxicity [23]. In contrast, seizures were more common in pediatric trials [4, 6, 7] and in adults after treatment with CD28-costimulated CAR products, but were not usually associated with a poor long-term outcome [50].

Acute cerebral edema is a life-threatening complication that has only been described after treatment with CD19-directed CAR-T cells. The occurrence of fatal cerebral edema in five patients led to the termination of a clinical trial in adults with ALL [24]. Deaths due to cerebral edema have been reported in clinical trials using CAR constructs containing either 4–1BB or CD28 co-stimulatory domains, in children and adults with ALL, and in adults with NHL and CLL [11, 23, 24, 45]. Cerebral edema can develop in a matter of hours, often while CRS is abating, and patients progress from mild confusion or somnolence to coma and brain death. Other fatal neurologic events after CD19 CAR-T cell therapy have included cortical necrosis, acute cerebral hemorrhage during resolving CRS, edema and hemorrhage of the brainstem and deep brain structures, multifocal thrombotic microangiopathy, and subacute encephalomalacia [6, 11, 23, 24]. Neuropathologic studies at autopsy after fatal neurotoxicity have demonstrated perivascular infiltration of CD8<sup>+</sup> T cells [11, 23], and CAR-T cells in brain tissue and CSF [23]. Widespread neuronal and white matter injury with macrophage infiltration and microglial activation have also been reported [11, 24].

### 3.2 Findings on Cerebrospinal Fluid Examination

Neurotoxicity is associated with increased CSF protein and white blood cell counts [23, 46], consistent with increased trafficking of cells and serum proteins across the blood–CSF barrier. Although CAR-T cells are detected in the CSF of most patients who undergo sampling during neurotoxicity, they can also be detected in the CSF of patients without neurotoxicity [23, 46, 47], suggesting that their presence in the CSF alone is not sufficient to induce neurologic dysfunction. We found that in patients with severe neurotoxicity, CD4<sup>+</sup> CAR-T cells were slightly enriched in CSF compared with blood, suggesting that central nervous system (CNS) migration may differ between CAR-T cell subsets. In a non-human primate model of CD20-directed CAR-T cells, neurotoxicity was associated with the accumulation of both CAR- and non-CAR-T cells in the CSF and in the brain parenchyma [48]. We observed high CSF levels of interferon- $\gamma$ , IL-6, tumor necrosis factor (TNF)- $\alpha$  and TNFRp55/p75 in patients with neurotoxicity, suggesting that the blood–brain barrier (BBB) may not prevent transit into the CSF of cytokines that circulate at high levels in the blood during CRS. Some studies have shown that some cytokines are present at higher levels in CSF compared with blood, suggesting increased production within the CNS [49].

### 3.3 Central Nervous System Imaging

Head imaging reveals several characteristic patterns associated with neurotoxicity. During mild neurotoxicity, imaging is frequently normal [5, 7, 23]. Common magnetic resonance imaging findings during neurotoxicity include reversible patchy T2 hyperintensities in the white matter, and symmetric T2 hyperintensities in the thalami and other deep gray matter structures [23, 44, 46]. These findings are indicative of interstitial edema and may be associated with microhemorrhages. Diffusion restriction in regions of cortical gray matter has also been observed, and can evolve into cortical laminar necrosis [23, 44]. Finally, global cerebral edema can be identified on imaging and is associated with devastating neurologic injury [23]. The heterogeneity of imaging findings suggests that different underlying mechanisms may be responsible for neurotoxicity.

### 3.4 Electroencephalography

The role of electroencephalography (EEG) monitoring in neurotoxicity is not yet well defined, although its routine use for risk assessment has been advocated [50]. In patients who underwent EEG, the most common finding was diffuse slowing, a non-specific indicator of encephalopathy that is common in critically ill patients. Causes can include medication effects, toxic metabolites, or hypoxia/ischemia [23, 50, 51]. In our clinical experience with children and adults, seizures were only detected on EEG in CAR-T cell-treated patients who also had clinically apparent seizures, while others have noted non-convulsive status epilepticus [50].

### 3.5 Grading of Neurotoxicity

Neurotoxicity signs and symptoms are typically graded using systems based on the Common Terminology Criteria for Adverse Events, with grades 1 through 5 representing mild, moderate, severe, life-threatening, and fatal toxicity, respectively. Some investigators have proposed modified grading systems. In our report of neurotoxicity in 133 adults treated with CD19 CAR-T cells incorporating 4-1BB co-stimulation, the presence of delirium or seizures resulted in a designation of grade 3 neurotoxicity because of the requirement for hospitalization. Gardner et al. used Common Terminology Criteria for Adverse Events grading, with the exception that seizures were designated as grade 3 neurotoxicity [4]. Neelapu et al. also assigned grade 3 neurotoxicity for any seizures, and added grade 4 for any motor weakness [50]. No grading systems have yet been shown to correlate with long-term clinical outcomes in prospectively validated studies.

## 4 Clinical Factors Associated with the Development of Neurotoxicity

The association of neurotoxicity with CRS is well recognized. Severe neurotoxicity is mainly seen in patients with concurrent or preceding CRS, and is uncommon in the absence of significant CRS [4, 6, 12, 21, 23, 46]. Neurotoxicity appears to present later than CRS, may take longer to resolve, and is less responsive to IL-6-targeted therapies than CRS. Most investigators consider neurotoxicity to be a related, but distinct, entity from CRS. The use of diverse CRS grading schemes [22, 26] makes it difficult to compare the impact of CRS on neurotoxicity between studies (Table 1). In a multivariate analysis of 133 adults treated with CD19 CAR-T cells at the Fred Hutchinson Cancer Research Center, we found that factors

leading to more severe CRS, such as higher in-vivo CAR-T cell numbers, higher CAR-T cell dose, higher tumor burden, and use of fludarabine in lymphodepletion resulted in a higher risk of neurotoxicity. Other investigators have also reported an association of neurotoxicity with higher pre-infusion tumor burden in ALL [23, 46] and greater peak CAR-T cell counts in vivo after infusion [12, 23, 46]. We also observed that pre-existing neurologic comorbidities were associated with an increased risk of neurotoxicity, although it is unknown which of these heterogenous conditions confers the greatest risk [23]. The design of the CAR (for example, incorporation of a CD28 or a 4-1BB co-stimulatory domain) and CAR-T cell manufacturing processes may also contribute to differences in the risk of neurotoxicity [52].

## 5 Biomarkers Associated with Neurotoxicity

### 5.1 Biomarkers During Acute Neurotoxicity

In patients with severe neurotoxicity, serum levels of several inflammatory mediators are higher after CAR-T cell infusion than in patients with grade 2 neurotoxicity. Consistently identified cytokines include IL-6 [12, 23, 44, 46], IL-10 [12, 44, 46], and interferon- $\gamma$  [23, 44, 46]. Associations of neurotoxicity with higher serum levels of C-reactive protein, ferritin, granulocyte-macrophage colony-stimulating factor, granzyme B, IL-15, IL-2, IL-2 receptor- $\alpha$ , IL-5, and TNF $\alpha$  [12, 23, 44, 46] have also been reported. None of these cytokines appear to be specific for neurotoxicity as they are also observed in elevated levels during severe CRS. Numerous cytokines are elevated in the CSF during acute neurotoxicity, likely owing to both increased BBB permeability and local production within the CNS [23, 44, 46]. In a non-human primate model of B cell-directed, CD20-targeted CAR-T cells, animals developed CRS and neurotoxicity associated with elevated serum levels of IL-6, IL-8, IL-1 receptor antagonist, MIG (CXCL9), and I-TAC (CXCL11); and disproportionately high levels of IL-6, IL-2, granulocyte-macrophage colony-stimulating factor, vascular endothelial growth factor, IL-1 $\beta$ , IL-1 receptor antagonist, monocyte chemoattractant protein-1 (MCP-1) [CCL2], and IP-10 (CXCL10) in the CSF compared with serum during in-vivo CAR-T cell expansion [48]. In a mouse model, monocyte-derived IL-1 but not IL-6 was identified as a targetable mediator of neurotoxicity [53]. Possible loss of microglia was seen in a mouse model of CAR-T cell-induced neurotoxicity [54].

Cytokine production by cell types other than infused CAR-T cells is not well understood. Autopsy studies in a patient with fatal CRS that was accompanied by mental status changes showed IL-6 expression by endothelial cells but not T cells [55], similar to endothelial responses seen with other inflammatory stimuli such as lipopolysaccharide challenge [56, 57]. Additionally, new insights from a xenogeneic model of CD19 CAR-T cell therapy have identified monocyte-derived IL-1 and IL-6 as key mediators of CRS [53]. In a different model, CRS was associated with down-regulation of macrophage inducible nitric oxide synthase [58]. In some patients with severe CRS and neurotoxicity, serum ferritin levels are markedly elevated, similar to those in macrophage activation syndrome and hemophagocytic lymphohistiocytosis, suggesting a role for macrophage activation in the pathophysiology [59].



We observed profound monocytopenia during severe neurotoxicity and CRS, which could be consistent with monocyte activation and extravasation into tissues. We and others have noted that consumptive coagulopathy was most pronounced in patients with severe neurotoxicity [23, 60]. The presence of elevated D-dimer, prothrombin, and activated partial thromboplastin times decreased fibrinogen and platelet counts, and high red cell and platelet transfusion requirements in the setting of hypotension and capillary leak suggested that vascular dysfunction and endothelial activation might be present during neurotoxicity [23]. A contribution from endothelial activation to neurotoxicity was supported by the observation that patients with grade 4 neurotoxicity had higher angiopoietin-2 and von Willebrand factor serum levels compared with patients with grade 3 neurotoxicity [23, 61]. In association with endothelial activation after CAR-T cell infusion, increased transit of interferon- $\gamma$  and TNF $\alpha$  across the BBB could induce stress and apoptosis of vascular supporting pericytes and potentially amplify increased endothelial permeability and BBB dysfunction [62, 63]. In support of this, pathologic examination of the brain of a patient with fatal neurotoxicity demonstrated endothelial activation with von Willebrand aggregation and a thrombotic microangiopathy with multifocal vascular disruption [23].

## 5.2 Candidate Predictive Biomarkers to Guide Early Intervention

Early recognition of patients at the highest risk of neurotoxicity might provide an opportunity for early intervention before severe neurotoxicity develops. In our study of neurotoxicity after 4-1BB co-stimulated CAR-T cell therapy, we found that in the first 36 h after CAR-T cell infusion, patients who subsequently developed the most severe neurotoxicity (grade 4) had higher serum MCP-1, IL-15, IL-10, and IL-2 in the first 36 h, as well as an earlier peak of IL-6 compared with those with grade 3 neurotoxicity [23]. We also found an increased angiopoietin-2:angiopoietin-1 ratio prior to lymphodepleting chemotherapy in patients who subsequently developed grade 4 neurotoxicity, indicating that pre-existing dysregulation of endothelial activation may increase neurotoxicity risk [23]. Algorithms based on levels of multiple cytokines within the first 24–36 h after CAR-T cell infusion predicted the development of neurotoxicity with high sensitivity and specificity, but may be impractical in the clinical setting where there is limited ability to perform such laboratory assays in real time [23, 64]. In our study, fever  $\geq 38.9$  °C alone within 36 h of CAR-T cell infusion had 100% sensitivity and 82% specificity for the development of life-threatening neurotoxicity, allowing the potential use of this simple clinical marker for risk stratification. The specificity was improved (94%) by the addition of a single serum assay for MCP-1 that was only performed on patients with fever  $\geq 38.9$  °C in the first 36 h after CAR-T cell infusion [23].

Others have proposed similar algorithms to predict the development of severe CRS [21, 65]. In a trial of CD28 costimulated CD19 CAR-T cells for patients with NHL, development of grade 3 neurotoxicity was associated with increased C-reactive protein, ferritin, IL-15, IL-16, IL-2 receptor- $\alpha$ , IL-6, and MCP-1 levels on the day immediately preceding CAR-T cell infusion [64]. Clearly, different approaches will likely be required for CAR-T cell products with distinct kinetics and presentations of neurotoxicity. Early intervention strategies using these biomarkers will require prospective validation in future clinical trials.

## 6 Management of Chimeric Antigen Receptor-T Cell-Associated Neurotoxicity

The role of disease-modifying interventions for neurotoxicity is debated, with some investigators using supportive care only, arguing that the vast majority of neurologic symptoms and signs resolve within 21 days after CAR-T cell infusion [6, 23]. Others advocate aggressive and early treatment with immunomodulators [50, 66]. Most patients with neurotoxicity also experience CRS, which may be treated with tocilizumab, an IL-6 receptor antibody, and/or corticosteroids to modulate T-cell activity [22, 67, 68], but the subsequent effect of these interventions on neurotoxicity is not well understood.

### 6.1 Tocilizumab

Tocilizumab is a humanized monoclonal antibody that targets cell-associated and soluble IL-6 receptor, blocking the binding of IL-6, a proinflammatory cytokine [69–71]. It was developed for the treatment of rheumatologic disorders [72] and approved by the FDA for use in rheumatoid arthritis [73], systemic juvenile idiopathic arthritis [74], and giant cell arteritis [75]. Its potential for treating CRS was considered in light of the high levels of IL-6 observed during CRS and the similarities with macrophage activation syndrome seen in systemic juvenile idiopathic arthritis [22, 76]. Retrospective analyses showed a sufficient likelihood of efficacy and safety in treating CAR-T cell-associated CRS, and it was approved by the FDA for this indication in 2017 [77]. Use of tocilizumab in patients with CRS as a result of robust CAR-T cell proliferation does not appear to affect anti-tumor response [4]; however, it is uncertain whether tocilizumab could affect efficacy when used prophylactically in patients with moderate or low levels of in-vivo CAR-T cell proliferation. No randomized controlled clinical trials of tocilizumab for CRS treatment have been conducted to date; nevertheless, its observed clinical efficacy has made it a mainstay for the treatment of severe CRS.

Evidence for the efficacy of tocilizumab in neurotoxicity is limited to published data from phase I and II clinical trials, although additional studies are underway [20, 23, 78]. In these trials, tocilizumab was used to treat CRS and/ or neurotoxicity in 23–48% of affected patients with ALL [2–7], 6–43% with NHL [9–12], and 0–25% with CLL [10, 14] (Table 1), but the indication for treatment (CRS vs. neurotoxicity) and outcomes of the intervention have not been consistently reported. Some clinical centers employ tocilizumab as a first-line therapy for neurotoxicity [50], whereas others do not use it at all for this indication [52].

A temporal association between the resolution of CRS symptoms and the development of neurotoxicity has been noted. Some investigators have considered that IL-6 receptor blockade with tocilizumab may lead to increased circulating IL-6 in the CNS, and possibly exacerbate neurotoxicity [79, 80]. Observational studies found that while early treatment with tocilizumab decreased the incidence of severe CRS, it was not associated with a decreased incidence or severity of neurotoxicity [45, 81].



## 6.2 Corticosteroids

Dexamethasone and other corticosteroids are used as first-line therapy for neurotoxicity by many groups [67, 81]. Dexamethasone has excellent CNS penetration and is a standard of care in the treatment of cerebral edema and inflammation in the setting of brain tumors and neurotrauma [82, 83]. High-dose methylprednisolone is generally reserved for more severe cases of CAR-T cell associated neurotoxicity, and is employed based on its well-studied effectiveness and safety in neuroinflammatory disorders [84, 85]. Because glucocorticoids can affect T-cell function [86], there has been concern that their use may decrease the efficacy of CAR-T cell immunotherapy. However, short courses of low-to moderate-dose corticosteroids (e.g. dexamethasone 10 mg twice daily for two to four doses or equivalent) administered to patients with toxicity due to robust CAR-T cell expansion do not appear to ablate CAR-T cell expansion or persistence, and do not have an obvious detrimental effect on anti-tumor efficacy [81]. High-dose corticosteroids (e.g., methylprednisolone 1 g/day) may result in profound lymphopenia and reduced circulating CAR-T cell counts; however, effects on anti-tumor efficacy have not been formally determined.

## 6.3 Other Biologics

Siltuximab is a chimeric monoclonal antibody that directly binds IL-6, preventing it from binding with soluble and membrane-bound IL-6 receptors [79, 87]. It has been used to manage CRS and/or neurotoxicity [88], and to manage neurologic adverse events during CAR-T cell treatment of glioblastoma [40]. Anakinra is a recombinant IL-1 receptor antagonist, which is FDA approved for the treatment of adult RA and neonatal-onset multisystem inflammatory disease. Anakinra is also effective in systemic juvenile idiopathic arthritis and has been used to manage life-threatening macrophage activation syndrome [89]. In a murine model of CAR-T cell-associated CRS and neurotoxicity, administration of anakinra at the time of CAR-T-cell infusion abrogated both CRS and neurotoxicity [53]. Other therapeutic approaches, such as plasma exchange, angiopoietin-1 augmentation, platelet hypertransfusion or small-molecule inhibition of cytokine signaling pathways, might be useful to treat CRS and neurotoxicity, but there are no data in humans to support their efficacy [90].

## 6.4 Anti-Seizure Prophylaxis

The role of anti-seizure prophylaxis for patients receiving CAR-T cell immunotherapy has not definitively been determined. Some CAR-T cell investigators start all patients on anti-seizure prophylaxis, some use it only for patients with CRS, and others do not use seizure prophylaxis at all [23, 50, 66]. Levetiracetam is frequently used for seizure prophylaxis, but the ideal timing, dose, and overall utility of this strategy are unknown. The adverse-event profile is favorable, and it does not have the marked effects on drug metabolism observed with some other anti-seizure medications.

## 6.5 Acute Management of Life-Threatening Neurotoxicity

Given the limited clinical experience with fulminant CAR-T cell-related neurotoxicity, it is not known what neurocritical care strategies are indicated in patients with cerebral edema or other rapidly progressive neurologic symptoms. Management may include standard

neuroprotective interventions for patients with suspected increased intracranial pressure, including treatment of fever, normocarbia or short-term mild hyperventilation, and optimizing cerebral perfusion by preventing hypotension, treating hypertension with caution, and keeping the head of bed midline position [91, 92]. Continuous EEG monitoring can be used to rule out subclinical seizures and monitor for changes in background electrical patterns, especially in critically ill patients with limited ability to participate in the exam [51]. Imaging findings of cerebral edema can be subtle even when clinical symptoms are well established, and should not be used alone for reassurance. Hyperosmolar therapy with mannitol or hypertonic saline, high-dose corticosteroids, sedation, and aggressive management of seizures are reasonable interventions for patients who have progressive and severe neurologic symptoms. There is no evidence that invasive neuromonitoring is helpful, and it is associated with significant risk as patients are frequently coagulopathic. Early detection of risk for deterioration is most likely the best method of preventing fulminant cerebral edema, as once established, it progresses rapidly and may not be reversible.

## 7 Conclusions

To further increase our understanding of neurotoxicity associated with CAR-T cell therapy, numerous lines of further investigation are needed. Ongoing characterization of the clinical features of neurotoxicity, particularly in patients who have received CAR-T cell immunotherapy targeting antigens other than CD19, and identification of long-term impacts of CAR-T cell immunotherapy on cognitive outcomes will be critical. Consensus criteria for grading of short-and long-term toxicities will be invaluable. Development of sensitive and specific methods for the prediction of severe neurotoxicity and testing of early intervention or prophylactic strategies will help improve the therapeutic index of CAR-T cells while maintaining anti-tumor efficacy. Finally, robust animal models will be invaluable for improving our understanding of the pathophysiology of neurotoxicity and the development of candidate treatments and prevention strategies as CAR-T cell therapy enters the mainstream of oncology.

## Acknowledgments

**Funding** No external funding was used in the preparation of this article.

## References

1. Chang ZL, Chen YY. CARs: synthetic immunoreceptors for cancer therapy and beyond. *Trends Mol Med.* 2017;23:430–50. [PubMed: 28416139]
2. Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. *N Engl J Med.* 2018;378:449–59. [PubMed: 29385376]
3. Turtle CJ, Hanafi L-A, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. *J Clin Investig.* 2016;126:2123–38. [PubMed: 27111235]
4. Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, et al. Intent to treat leukemia remission by CD19CAR T cells of defined formulation and dose in children and young adults. *Blood.* 2017;22(129):3322–31.

5. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Del-brook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. *Lancet*. 2015;385:517–28. [PubMed: 25319501]
6. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bitten-court H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. *N Engl J Med*. 2018;378:439–48. [PubMed: 29385370]
7. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. *N Engl J Med*. 2014;371:1507–17. [PubMed: 25317870]
8. Annesley CE, Summers C, Ceppi F, Gardner RA. The evolution and future of CAR T cells for B-cell acute lymphoblastic leukemia. *Clin Pharmacol Ther*. 2018;103:591–8. [PubMed: 29171004]
9. Turtle CJ, Hanafi L-A, Berger C, Hudecek M, Pender B, Robin-son E, et al. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8<sup>+</sup> and CD4<sup>+</sup> CD19-specific chimeric antigen receptor-modified T cells. *Sci Transl Med*. 2016;8:355ra116.
10. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RPT, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. *J Clin Oncol*. 2015;33:540–9. [PubMed: 25154820]
11. Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. *N Engl J Med*. 2017;377:2545–54. [PubMed: 29226764]
12. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. *N Engl J Med*. 2017;377:2531–44. [PubMed: 29226797]
13. Brudno JN, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for lymphoma. *Nat Rev Clin Oncol*. 2018;15:31–46. [PubMed: 28857075]
14. Turtle CJ, Hay KA, Hanafi L-A, Li D, Cherian S, Chen X, et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib. *J Clin Oncol*. 2017;35:3010–20. [PubMed: 28715249]
15. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. *Sci Transl Med*. 2013;5:177ra38.
16. Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. *Nat Med*. 2018;24:563–71. [PubMed: 29713085]
17. US Food and Drug Administration. Approved products: Kymriah (tisagenlecleucel). <https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm573706.htm>. Accessed 14 May 2018.
18. Friedman KM, Garrett TE, Evans JW, Horton HM, Latimer HJ, Seidel SL, et al. Effective targeting of multiple B-cell maturation antigen-expressing hematological malignancies by anti-B-cell maturation antigen chimeric antigen receptor T cells. *Hum Gene Ther*. 2018;29:585–601. [PubMed: 29641319]
19. Chen N, Li X, Chintala NK, Tano ZE, Adusumilli PS. Driving CARs on the uneven road of antigen heterogeneity in solid tumors. *Curr Opin Immunol*. 2018;51:103–10. [PubMed: 29554494]
20. Hay KA, Hanafi L-A, Li D, Gust J, Liles WC, Wurfel MM, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. *Blood*. 2017;130:2295–306. [PubMed: 28924019]
21. Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. *Cancer Discov*. 2016;6:664–79. [PubMed: 27076371]
22. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. *Blood*. 2014;124:188–95. [PubMed: 24876563]
23. Gust J, Hay KA, Hanafi L-A, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial activation and blood–brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. *Cancer Discov*. 2017;7:1404–19. [PubMed: 29025771]

24. DeAngelo DJ, et al. Clinical outcomes for the phase 2, single-arm, multicenter trial of JCAR015 in adult B-ALL (ROCKET Study) [abstract P217]. *J Immunother Cancer*. 2017;5:86.
25. Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. *Blood*. 2011;118:4817–28. [PubMed: 21849486]
26. Porter D, Frey N, Wood PA, Weng Y, Grupp SA. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. *J Hematol Oncol*. 2018;11(1):35. [PubMed: 29499750]
27. Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirectioned lymphocytes. *J Clin Investig*. 2017;127:3462–71. [PubMed: 28805662]
28. Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. *Nat Med*. 2018;24:20. [PubMed: 29155426]
29. Wang C-M, Wu Z-Q, Wang Y, Guo Y-L, Dai H-R, Wang X-H, et al. Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial. *Clin Cancer Res*. 2017;23:1156–66. [PubMed: 27582488]
30. Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. *Blood*. 2016;128:1688–700. [PubMed: 27412889]
31. Ritchie DS, Neeson PJ, Khot A, Peinert S, Tai T, Tainton K, et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. *Mol Ther J Am Soc Gene Ther*. 2013;21:2122–9.
32. Yeku O, Li X, Brentjens RJ. Adoptive T-cell therapy for solid tumors. *Am Soc Clin Oncol Educ Book*. 2017;37:193–204. [PubMed: 28561728]
33. Newick K, O'Brien S, Moon E, Albelda SM. CAR T cell therapy for solid tumors. *Annu Rev Med*. 2017;68:139–52. [PubMed: 27860544]
34. Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, et al. Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. *J Clin Oncol*. 2015;33:1688–96. [PubMed: 25800760]
35. Feng K, Guo Y, Dai H, Wang Y, Li X, Jia H, et al. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. *Sci China Life Sci*. 2016;59:468–79. [PubMed: 26968708]
36. Junghans RP, Ma Q, Rathore R, Gomes EM, Bais AJ, Lo ASY, et al. Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response. *Prostate*. 2016;76:1257–70. [PubMed: 27324746]
37. Lamers CH, Sleijfer S, van Steenberg S, van Elzakker P, van Krimpen B, Groot C, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. *Mol Ther J Am Soc Gene Ther*. 2013;21:904–12.
38. Thistlethwaite FC, Gilham DE, Guest RD, Rothwell DG, Pillai M, Burt DJ, et al. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. *Cancer Immunol Immunother*. 2017;66:1425–36. [PubMed: 28660319]
39. Zhang C, Wang Z, Yang Z, Wang M, Li S, Li Y, et al. Phase I escalating-dose trial of CAR-T therapy targeting CEA<sup>+</sup> metastatic colorectal cancers. *Mol Ther J Am Soc Gene Ther*. 2017;25:1248–58.
40. O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrisette JJD, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. *Sci Transl Med*. 2017;9(399):eaaa0984. 10.1126/scitranslmed.aaa0984.
41. Brown CE, Badie B, Barish ME, Weng L, Ostberg JR, Chang W-C, et al. Bioactivity and safety of IL13R $\alpha$ 2-redirectioned chimeric antigen receptor CD8<sup>+</sup> T cells in patients with recurrent glioblastoma. *Clin Cancer Res*. 2015;21:4062–72. [PubMed: 26059190]

42. Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. *N Engl J Med.* 2016;375:2561–9. [PubMed: 28029927]
43. Prudent V, Breitbart WS. Chimeric antigen receptor T-cell neuropsychiatric toxicity in acute lymphoblastic leukemia. *Palliat Support Care.* 2017;15:499–503. [PubMed: 28049548]
44. Gust J, Finney O, Gardner R. Brain inflammation in CD19 CAR T cell treatment-related neurotoxicity. Whistler (BC), Canada 2017 <https://virtual.keystonesymposia.org/ks/articles/767/view>. Accessed 27 Apr 2018.
45. Locke FL, Neelapu SS, Bartlett NL, Lekakis LJ, Jacobson CA, Braunschweig I, et al. Preliminary results of prophylactic tocilizumab after axicabtageneclixoleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-Hodgkin lymphoma (NHL). *Blood.* 2017;130:1547.
46. Santomaso B, Park JH, Riviere I, Mead E, Halton E, Diamonte C, et al. Biomarkers associated with neurotoxicity in adult patients with relapsed or refractory B-ALL (R/R B-ALL) treated with CD19 CAR T cells. *J Clin Oncol.* 2017;35:3019.
47. Rheingold SR, Chen LN, Maude SL, Aplenc R, Barker C, Barrett DM, et al. Efficient trafficking of chimeric antigen receptor (CAR)-modified T cells to CSF and induction of durable CNS remissions in children with CNS/combined relapsed/refractory ALL. *Blood.* 2015;126:3769.
48. Taraseviciute A, Tkachev V, Ponce R, Turtle CJ, Snyder JM, Liggitt HD, et al. Chimeric antigen receptor T cell-mediated neurotoxicity in non-human primates. *Cancer Discov.* 2018;8:750–63. [PubMed: 29563103]
49. Santomaso BD, Park JH, Salloum D, Rivière I, Flynn J, Mead E, et al. Clinical and biologic correlates of neurotoxicity associated with CAR T cell therapy in patients with B-cell acute lymphoblastic leukemia (B-ALL). *Cancer Discov.* 2018;8:958–71. [PubMed: 29880584]
50. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy: assessment and management of toxicities. *Nat Rev Clin Oncol.* 2018;15:47–62. [PubMed: 28925994]
51. Herman ST, Abend NS, Bleck TP, Chapman KE, Drislane FW, Emerson RG, et al. Consensus statement on continuous EEG in critically ill adults and children. Part I: indications. *J Clin Neurophysiol.* 2015;32:87–95.
52. Grupp S. Beginning the CAR T cell therapy revolution in the US and EU. *Curr Res Transl Med.* 2018;66:62–4. [PubMed: 29656949]
53. Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. *Nat Med.* 2018;24(6):739–48. [PubMed: 29808007]
54. Pennell CA, Barnum JL, McDonald-Hyman CS, Panoskaltsis-Mortari A, Riddle MJ, Xiong Z, et al. Human CD19-targeted mouse T cells induce B cell aplasia and toxicity in human CD19 transgenic mice. *Mol Ther.* 2018;26:1423–34. [PubMed: 29735365]
55. Obstfeld AE, Frey NV, Mansfield K, Lacey SF, June CH, Porter DL, et al. Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights. *Blood.* 2017;130:2569–72. [PubMed: 29074500]
56. Jirik FR, Podor TJ, Hirano T, Kishimoto T, Loskutoff DJ, Carson DA, et al. Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. *J Immunol.* 1989;142:144–7. [PubMed: 2783321]
57. Reyes TM, Fabry Z, Coe CL. Brain endothelial cell production of a neuroprotective cytokine, interleukin-6, in response to noxious stimuli. *Brain Res.* 1999;851:215–20. [PubMed: 10642846]
58. Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. *Nat Med.* 2018;24:731–8. [PubMed: 29808005]
59. Rosário C, Zandman-Goddard G, Meyron-Holtz EG, D’Cruz DP, Shoenfeld Y. The hyperferritinemic syndrome: macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome. *BMC Med.* 2013;11:185. [PubMed: 23968282]
60. Park JH, Santomaso B, Riviere I, Senechal B, Wang X, Purdon T, et al. Baseline and early post-treatment clinical and laboratory factors associated with severe neurotoxicity following 19–28z CAR T cells in adult patients with relapsed B-ALL. *J Clin Oncol.* 2017;35:7024.



61. Page AV, Liles WC. Biomarkers of endothelial activation/dysfunction in infectious diseases. *Virulence*. 2013;4:507–16. [PubMed: 23669075]
62. Argaw AT, Gurfein BT, Zhang Y, Zameer A, John GR. VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. *Proc Natl Acad Sci USA*. 2009;106:1977–82. [PubMed: 19174516]
63. Rochfort KD, Collins LE, McLoughlin A, Cummins PM. Tumour necrosis factor- $\alpha$ -mediated disruption of cerebrovascular endothelial barrier integrity in vitro involves the production of proinflammatory interleukin-6. *J Neurochem*. 2016;136:564–72. [PubMed: 26499872]
64. Locke F, Sherman M, Rossi J, et al. Early biomarker correlates of severe neurologic events and cytokine release syndrome in ZUMA-1, a multicenter trial evaluating axicabtagene ciloleucel in refractory aggressive non-Hodgkin lymphoma. *J Immunother Cancer*. 2017 <https://jitc.biomedcentral.com/articles/10.1186/s40425-017-0289-3>. Accessed 18 Oct 2018.
65. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia. *Sci Transl Med*. 2014;6:224ra25.
66. Teachey DT, Bishop MR, Maloney DG, Grupp SA. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit “ALL”. *Nat Rev Clin Oncol*. 2018;15:218.
67. Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. *Blood*. 2016;127:3321–30. [PubMed: 27207799]
68. Gauthier J, Turtle CJ. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. *Curr Res Transl Med*. 2018;66(2):50–2. [PubMed: 29625831]
69. Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. *Nat Med*. 2000;6:583–8. [PubMed: 10802717]
70. Mihara M, Nishimoto N, Ohsugi Y. The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. *Expert Opin Biol Ther*. 2005;5:683–90. [PubMed: 15934843]
71. Venkiteswaran A. Tocilizumab. *mAbs*. 2009;1:432–8. [PubMed: 20065633]
72. Rubbert-Roth A, Furst DE, Nebesky JM, Jin A, Berber E. A review of recent advances using tocilizumab in the treatment of rheumatic diseases. *Rheumatol Ther*. 2018;5(1):21–42. [PubMed: 29502236]
73. Curtis JR, Perez-Gutthann S, Suissa S, Napalkov P, Singh N, Thompson L, et al. Tocilizumab in rheumatoid arthritis: a case study of safety evaluations of a large postmarketing data set from multiple data sources. *Semin Arthritis Rheum*. 2015;44:381–8. [PubMed: 25300699]
74. Tarp S, Amarilyo G, Foeldvari I, Christensen R, Woo JMP, Cohen N, et al. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials. *Rheumatol Oxf Engl*. 2016;55:669–79.
75. Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of tocilizumab in giant-cell arteritis. *N Engl J Med*. 2017;377:317–28. [PubMed: 28745999]
76. Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. *Blood*. 2015;125:4017–23. [PubMed: 25999455]
77. Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. *Oncologist*. 2018;23(8):943–7. [PubMed: 29622697]
78. ClinicalTrials.gov. Study of the tocilizumab optimization timing for CART19 associated cytokine release syndrome. <https://clinicaltrials.gov/ct2/show/NCT02906371>. Accessed 29 Sept 2018.
79. Chen F, Teachey DT, Pequignot E, Frey N, Porter D, Maude SL, et al. Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. *J Immunol Methods*. 2016;434:1–8. [PubMed: 27049586]
80. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. *Blood*. 2008;112:3959–64. [PubMed: 18784373]



81. Gardner R, Leger KJ, Annesley CE, Summers C, Rivers J, Gust J, et al. Decreased rates of severe CRS seen with early intervention strategies for CD19 CAR-T cell toxicity management. *Blood*. 2016;128:586.
82. Koehler PJ. Use of corticosteroids in neuro-oncology. *Anticancer Drugs*. 1995;6:19–33.
83. Michinaga S, Koyama Y. Pathogenesis of brain edema and investigation into anti-edema drugs. *Int J Mol Sci*. 2015;16:9949–75. [PubMed: 25941935]
84. Berkovich RR. Acute multiple sclerosis relapse. *Contin Minneap Minn*. 2016;22:799–814.
85. Wingerchuk DM, Weinshenker BG. Acute disseminated encephalomyelitis, transverse myelitis, and neuromyelitis optica. *Contin Minneap Minn*. 2013;19:944–67.
86. Elenkov IJ. Glucocorticoids and the Th1/Th2 balance. *Ann N Y Acad Sci*. 2004;1024:138–46. [PubMed: 15265778]
87. Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. *Clin Cancer Res*. 2013;19:3659–70. [PubMed: 23659971]
88. Shah B, Huynh V, Sender LS, Lee DW, Castro JE, Wierda WG, et al. High rates of minimal residual disease-negative (MRD–) complete responses (CR) in adult and pediatric patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) treated with KTE-C19 (anti-CD19 chimeric antigen receptor [CAR] T cells): preliminary results of the ZUMA-3 and ZUMA-4 trials. *Blood*. 2016;128:2803.
89. Grevich S, Shenoi S. Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition. *Adolesc Health Med Ther*. 2017;8:125–35. [PubMed: 29184458]
90. Saharinen P, Eklund L, Alitalo K. Therapeutic targeting of the angiotensin-TIE pathway. *Nat Rev Drug Discov*. 2017;16:635–61. [PubMed: 28529319]
91. Chesnut RM, Temkin N, Dikmen S, Rondina C, Videtta W, Petroni G, et al. A method of managing severe traumatic brain injury in the absence of intracranial pressure monitoring: the imaging and clinical examination protocol. *J Neurotrauma*. 2018;35:54–63. [PubMed: 28726590]
92. Kukreti V, Mohseni-Bod H, Drake J. Management of raised intracranial pressure in children with traumatic brain injury. *J Pediatr Neurosci*. 2014;9:207–15. [PubMed: 25624921]

### Key Points

Neurotoxicity is a common complication of chimeric antigen receptor-T cell therapy for hematologic malignancies, which is typically self-limited but can be life threatening or fatal.

Neurotoxicity is associated with an elevation of serum and cerebrospinal fluid cytokines, including interleukin-6 and interferon- $\gamma$ , and systemic cytokine release syndrome is strongly associated with the development of neurotoxicity.

Commonly used therapeutic approaches, including corticosteroids and interleukin-6 blockade, require further study, and there is a need for standardized grading, monitoring, prevention, and treatment of neurologic complications of chimeric antigen receptor-T cell therapy.

**Table 1**  
Neurotoxicity in CD19-directed chimeric antigen receptor (CAR) T cell clinical trials

References (first author, year)	NCT	N	Age range (Years)	CAR construct	Lympho-depletion (N)	CRR (%)	ORR (%)	NT (%)	sNT (%)	CRS <sup>a</sup> (%)	sag <sup>a</sup> (%)	LoCI (%)	steroids (%)
ALL													
Lee, 2015 [5]	NCT01593696	20	5–27	28z	Flu/Cy	70 <sup>g</sup> 60 <sup>h</sup>	n/a	30	5	75 <sup>c*</sup>	30	27	13
Gardner, 2017 [4]	NCT02028455	43	1–25	4-1BB	Cy (27) or Flu/Cy (14)	93 <sup>h</sup> 93 <sup>h</sup>	n/a	44	21 <sup>b</sup>	93 <sup>c*</sup>	23	42	25
Maude, 2018 [6]	NCT02435849	75	3–23	4-1BB(tisagenle-ckuceel)	Flu/Cy (71) or Cy/Etop (1)	81 <sup>g</sup> 81 <sup>h</sup>	n/a	40	13	77 <sup>p</sup>	46	48	0
Maude, 2014 [7]	NCT01626495 NCT01029366	30	5–60	4-1BB(CTL019, tisafnlecleuceel)	Cy/VP (5), Ara-C/Etop (1), Flu/Cy (15), Cy (3), Clo (1), CVAD-A (1), or CVAD-B (1)	90 <sup>g</sup> 79 <sup>h</sup>	n/a	43	NR	88 <sup>*</sup>	27	30	20
Turtle, 2016 [3] <sup>c</sup>	NCT01865617	30	20–73	4-1BB	Cy/Etop (2), Cy (11), or Flu/Cy (17)	100 <sup>g</sup> 93 <sup>h</sup>	n/a	50	50	83 <sup>c</sup>	23	27	37
Park, 2018 [2]	NCT01044069	53	23–74	28z (19–28z)	Cy (43) or Flu/cy (10)	83 <sup>g</sup> 67 <sup>h</sup>	n/a	44	42	85 <sup>M</sup>	26	42	38
NHL													
Kochenderfer, 2015 [10]	NCT00924326	11	30–68	28z	Flu/Cy (15)	36	80	NR	45	NR <sup>c</sup>	36	25	0
Turtle, 2016 [9]	NCT01865617	32	36–70	4-1BB	Cy or Cy/Etop (12) or Flu/Cy (20)	33	63	28	28 <sup>d</sup>	63 <sup>c*</sup>	13	9	13
Schuster, 2017 [11]	NCT02030834	28	25–77	4-1BB (CTL019)	Cy (11), modEPOCH (3), bend (8), Cy/T81 (4), Cy/Etop (1), Flu/Cy (1), Carbo/Gem (10)	57	64	39	11	57 <sup>p</sup>	18	20	6
Neeclapu, 2017 [12]	NCT07248216	101	23–76	28z (axicabtagene cixaleuceel)	Flu/Cy (101)	54	82	64	28	93 <sup>L</sup>	13	43	27
CLL													
Turtle, 2017 [14] <sup>c</sup>	NCT01865617	24	40–73	4-188	Cy (1), Flu (2) Flu/Cy (21)	29	71	33	25 <sup>d</sup>	83 <sup>L</sup>	8	25	25

References (first author, year)	NCT	N	Age range (Years)	CAR construct	Lympho-depletion (N)	CRR (%)	ORR (%)	NT (%)	sNT (%)	CRS <sup>a</sup> (%)	sag <sup>a</sup> (%)	Loci (%)	steroids (%)
Fraietta, 2018 [16]	NCT01029366 NCT01747486 NCT02640209	41	61–66 <sup>e</sup>	4–188	n/a	20	39	6 <sup>f</sup>	0 <sup>f</sup>	69 <sup>f</sup>	38 <sup>f</sup>	NR	NR

4-1BB 4-1BB costimulatory domain, 28z CD28-CD3zeta costimulatory domain, ALL acute lymphoblastic leukemia, *Arm-C* cytarabine, *BezD* bendamustine, *Carbo* carboplatin, *CHOP* Children's Hospital of Philadelphia, *CLL* chronic lymphocytic leukemia, *c/o* clofarabine, *CRR* complete remission rate, *CRS* cytokine release syndrome, *CTCAE* Common Terminology Criteria for Adverse Events, *CVAD-A* cyclophosphamide + vincristine + adriamycin, *CVAD-B* methotrexate + cytarabine, *Cy* cyclophosphamide, *Etop* etoposide, *Flu* fludarabine, *Gem* gemcitabine, *mod-EPOCH* modified EPOCH (doxorubicin, etoposide, cyclophosphamide), *MSKCC* Memorial Sloan Kettering Cancer Center, *n/a* not available, *NCT* national clinical trial, *NHL* non-Hodgkin's lymphoma, *NR* reported, *NT* neurotoxicity, *ORR* overall response rate, *sCRS* severe CRS (CTCAE grade 3 or greater, or as defined in the publication), *sNT* severe neurotoxicity (CTCAE grade 3 or greater), *steroids* corticosteroids, *TBI* total body irradiation, *toc* tocilizumab, *VP* etoposide

<sup>a</sup>The CRS grading system is indicated by the following superscripts: C = CTCAE criteria; L = Lee criteria [22]; P = Penn/CHOP criteria [26]; M = MSKCC criteria [2];

\* indicates modified criteria, please refer to the individual publication for details

<sup>b</sup> CTCAE grade 3 or greater, and/or any seizures

<sup>c</sup> Data on expanded cohort available in [23]

<sup>d</sup> CTCAE grade 3 or greater, and/or any seizures, and/or grade 2 delirium

<sup>e</sup> Only median age reported

<sup>f</sup> Toxicities only reported for the 16 patients who responded to CAR T cells

<sup>g</sup> Morphologic remission

<sup>h</sup> Minimal residual disease-negative remission

**Table 2**  
Neurotoxicity in selected non-CD 19-directed chimeric antigen receptor (CAR) T cells for hematologic malignancies

References (first author, year)	NCI	N	Age group	CAR target	CAR construct	Disease	CRR (%)	sNT (%)	NT (%)	CRS (%)	sCRS (%)	toxi (%)	steroids (%)
Fry, 2018 [28]	NCT02315612	21	Peds, adult	CD22	4-1BB	ALL (majority CD19 CAR pretreated)	57 <sup>a</sup> 43 <sup>b</sup>	0	25	76	0	0	0
Ramos, 2017 [27]	NCT01316146	9	Adult	CD30	28z	HL, ALCL	33	0	0	0	0	n/a	n/a
Wang, 2017 [29]	NCT02259556	18	Peds, adult	CD30	4-1BB	HL	0	0	0	0	0	n/a	n/a
Ali, 2016 [30]	NCT02215967	12	Adult	BCMA	28z	MM	8	8	25	50	25	33	0
Ritchie, 2013 [31]	CTX 08-0002	4	Adult	LeY	28z	AML	25	0	0	25	0	0	0

4-1BB 4-1BB co-stimulatory domain, 28z CD28 co-stimulatory domain. ALCL anaplastic large cell lymphoma. ALL acute lymphoblastic leukemia. AML acute myelogenous leukemia. BCMA B-cell maturation antigen. CRR complete remission rate. CRS cytokine release syndrome. HL Hodgkin's lymphoma. MM multiple myeloma. n/a not available. NCI national clinical trial. NT neurotoxicity. peds pediatrics, sCRS severe CRS, sNT severe neurotoxicity (Common Terminology Criteria for Adverse Events grade 3 or higher), steroids corticosteroids. toxi toxicities.

<sup>a</sup>Morphologic remission

<sup>b</sup>Minimal residual disease-negative remission